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To the Editor: Childhood splenectomy exposes patients to increased risk of bacterial infections. Appropriate vaccination and education have helped combat these; however, insufficient attention is paid to viral infections after splenectomy. Herein, we report a case of cold agglutinin disease (CAD) caused by recurrent viral infections after splenectomy to treat childhood immune thrombocytopenic purpura (ITP). Antiviral and immunostimulant therapies were administered, resulting in an improved general condition.
The patient had suffered from recurrent epistaxis and skin hemorrhagic spots since he was 10 years old. A complete blood count and smear revealed thrombocytopenia; the lowest platelet count was 1 × 10 9 /L. Bone marrow analysis indicated a diagnosis of ITP. He was administered corticosteroids and intravenous immunoglobulins subsequently; however, they were ineffective. Therefore, the patient underwent splenectomy to treat ITP at the age of 11 years. Postsplenectomy, his platelet count increased to an average of 500 × 10 9 /L with a highest recorded count of 840 × 10 9 /L. Mutations of JAK2V617F, JAK2 exon 12, MPL W515L/K, and CALR were negative. Verruca first developed on his big toes, one year after splenectomy, and spread to all four limbs and the trunk thereafter [ Figure 1 ]. Skin biopsy revealed verrucous proliferation, confirming this diagnosis. He received immunostimulant drugs, interferon, Chinese medicine, and cryotherapy, but with no efficacy. He also had acute posterior ganglionitis a year after the splenectomy, which was controlled with antiviral treatment.
This 24-year-old Chinese man was referred to our hospital in May 2016, with a chief complaint of dizziness and fatigue for one year. The well-defined verruca was round, rough and grayish yellow, with skin keratinization on the surface (a). Posttreatment, the skin lesions were gradually subsiding (b).
b a neutrophil, 3.7 × 10 9 /L; lymphocyte, 1.3 × 10 9 /L; platelets, 150 × 10 9 /L; and reticulocytes, 2.5%). Erythrocyte sedimentation rate has decreased to 8 mm/h. EBV-DNA dropped below the detection threshold (<1 × 10 −2 copies/ml) posttreatment. The cold agglutinin titer reduced to 1:256. Indirect and direct bilirubin levels were 13.8 mmol/L and 7.0 mmol/L, respectively.
CAD is a kind of cold autoimmune hemolytic anemia (AIHA) accounting for 10-20% of all AIHA cases. CAD may be idiopathic or secondary. Lymphocytic malignancies and infections (e.g., MP or infectious mononucleosis) are the most frequent underlying diseases for secondary CAD. [1] Positive IgG for MP indicates past infection, whereas positive EBV-DNA and virus capsid antigen IgA reveals current infection. Moreover, the role of concomitant human papillomavirus infection in the development of CAD is unclear. Keeping warm is the main principle for the treatment of CAD. CAD in this patient is likely to have been secondary to his viral infection, which should be treated to relieve the hemolysis. Therefore, antiviral and immunostimulant therapies were administered. The viral infections were controlled, resulting in an improved general condition and proving the effectiveness of the treatment. Rituximab, alone or in combination with other drugs, was satisfactorily effective in the treatment of CAD in both retrospective and prospective studies. [2, 3] In addition, other novel therapies such as eculizumab [4] and bortezomib [5] are emerging.
The spleen is the largest accumulation of lymphoid tissue and exhibits important immunological functions. In infants and children, splenectomy is conducted mostly to treat splenic trauma, hereditary spherocytosis, and ITP. Splenectomized children are immunocompromised and are at high risk for bacterial infections. The case we reported indicated that viral infections and subsequent complications such as CAD should also be considered in children who have undergone splenectomy to treat ITP. Antiviral and immunostimulant treatments might be useful in such patients to treat viral infections.
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